Zimbabwe study targets cancer prevention with vaccines and mental health care

NCT ID NCT06786429

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study in Zimbabwe will screen women of childbearing age and high school students for HPV and Hepatitis B, then offer vaccines to those who are eligible. It also includes cognitive behavioral therapy for mental health issues. The goal is to see if this combined approach can prevent cervical and liver cancers in these groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Gardasil 9 vaccine, Hepatitis B Virus Vaccine (HBV), Cognitive Behavioral Therapy

What this could lead to

If successful, this approach could reduce cervical and liver cancer rates in Zimbabwe by combining vaccination, screening, and mental health support.

What could go wrong

This is an observational study with a large sample, but it does not test a new treatment. Results may not apply to other regions, and vaccine uptake or follow-up may be limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anxiety disorder cervical carcinoma Depression depressive disorder gallstones hepatitis B virus infection hepatocellular carcinoma human papilloma virus infection mixed anxiety and depressive disorder Uterine Cervical Neoplasms cervical cancer prevention target liver cancer prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••